Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 4

Conditions: Sedation

Treatments: Drug: morphine; Drug: propofol; Drug: remifentanil; Drug: midazolam; Drug: lorazepam; Drug: fentanyl

Study type: Interventional

Funder types: Industry

Identifiers

NCT00158873

101653

Details and patient eligibility

About

The study will evaluate the pharmaco-economic consequences of the use of a remifentanil based regimen compared with a conventional sedative based regimen in terms of duration of mechanical ventilation, length of stay in ICU, difference in extubation time and use of concomitant sedative agents.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ICU patients with an expected duration of mechanical ventilation for 2 to 3 days and requiring analgesia and sedation.

Exclusion criteria

• ICU patients resuscitated in the previous 24 hours, neurotrauma or expecting major surgery, not likely to survive of with limit care status.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)